Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q3 FY22 results · Oct–Dec 2021

Zydus Lifesciences reported revenue from operations of ₹3,655.00 crore (down 3.7% from Q3 FY21) and net profit of ₹510.60 crore (down 3.3% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	3,655.00	3,795.60	−3.7%	3,784.80	−3.4%
Other income	60.80	27.50	+121.1%	53.30	+14.1%
Total income	3,715.80	3,823.10	−2.8%	3,838.10	−3.2%
Profit before share of associates & JVs and tax	599.00	627.20	−4.5%	603.50	−0.7%
Share of profit/(loss) of associates & JVs	22.30	15.50		12.30
Net profit for the period	510.60	528.00	−3.3%	3,011.90	−83.0%
Attributable to shareholders of the company	500.40	527.20	−5.1%	3,002.30	−83.3%
EPS, basic (₹)	4.89	5.15	−5.0%	29.32	−83.3%
Net margin (%)	14.0	13.9		79.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	1,830.30	1,918.80	−4.6%	2,008.90	−8.9%
Other income	25.90	25.00	+3.6%	69.40	−62.7%
Total income	1,856.20	1,943.80	−4.5%	2,078.30	−10.7%
Profit before tax	239.90	206.90	+15.9%	91.10	+163.3%
Net profit for the period	197.00	140.30	+40.4%	14.10	14x
EPS, basic (₹)	1.92	1.37	+40.1%	0.14	14x
Net margin (%)	10.8	7.3		0.7

Consolidated

Filed with BSE: 03 Feb 2022, 15:01 IST
Board meeting: 03 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 03 Feb 2022, 15:01 IST
Board meeting: 03 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE